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Complement-Induced Post-Translational Regulation of TGF-ß Signaling on 
Endothelial Cells  
Kevin Liu and Dan Jane-Wit, MD/PhD. Section of Cardiovascular Medicine, Department of 




Cardiac allograft vasculopathy (CAV) is a complex vaso-occlusive complication of heart 
transplantation currently identified as a major limiting factor to long-term survival in those who 
receive a cardiac transplant. In CAV, neointimal lesions form in graft vessels leading to ischemic 
complications and ultimately allograft loss. CAV is medically untreatable and affects ~50% of 
heart transplant patients. Endothelial cells (ECs) are a critical site where CAV lesions form, and 
antibodies produced by the recipient that bind to donor HLA molecules on graft endothelium 
(donor specific antibodies) have been identified as a key mediator in this process. Recent studies 
have further identified a role for antibody-mediated complement fixation, specifically in 
determining pro-inflammatory signaling changes induced through this process. The laboratory 
of my mentor, Dr. Jane-wit, studies complement-mediated signaling in ECs and has previously 
identified a signaling pathway implicated in CAV. In an unbiased assay to identify new 
components of this pathway, I unexpectedly found that TGF-ß signaling molecules, canonically 
understood to be anti-inflammatory, were involved in complement-induced EC activation. 
During my thesis I defined a novel function for proteasomes as cellular chaperones to activate 
TGF-ß signaling in response to complement activation. My thesis studies identify a pathologic 
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1.1 Heart Failure and Advanced Heart Failure: Prognosis and Treatment Modalities 
Heart failure (HF) is a complex chronic and progressive syndrome resulting from 
structural or functional impairments in ventricular filling or ejection of blood.1 
Diagnosis is made clinically, and manifestations of HF include dyspnea and fatigue 
limiting exercise tolerance and fluid retention leading to pulmonary and peripheral 
congestion/edema.1 In the US, for those over 40 years of age, the risk of developing HF 
is 20% with stable incidence.1 Prevalence of HF is estimated to be greater than 5 million 
persons and increasing.1,2 The increasing prevalence in context of stable incidence is 
thought to be due to evolving advancements in treatment options, including renin-
angiotensin-aldosterone antagonists, beta-blockers, and implantable cardioverter-
defibrillators.2 A subset of those with HF are those with advanced or AHA Stage D HF 
(refractory HF) requiring specialized interventions in any NYHA functional class.1 
Etiologies vary from those with chronic HF and specific risk factors, such as diabetes 
mellitus, obesity, hypertension, and chronic kidney disease, to acute major insults 
(fulminant myocarditis, acute myocardial infarction with cardiogenic shock).2-5 
Advanced HF is defined as persistent symptoms of HF despite optimal medical therapy 
and is estimated to affect <1% to 25% of patients with heart failure with best estimates 
being around 5% from the Acute Decompensated Heart Failure national registry 
(ADHERE LM).2-4 Treatment for those with advanced HF is often limited to advanced 
surgical HF therapies including left ventricular assist devices (LVADs) or cardiac 
transplantation as those on optimal medical therapy were found to have extremely poor 
prognoses as demonstrated in the medical arm (compared to LVAD) of the REMATCH 
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(Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive 
Heart Failure) trial.2,4,6 Specifically, survival at 1 and 2 years in the medical treatment 
arm of advanced HF was found to be 25% and 8% respectively compared to 52% and 
23% in the LVAD group.2,6 While innovations in LVAD technologies have significantly 
improved since the REMATCH trial (especially centering around continuous flow 
technologies), those who receive a transplant still have the best long-term course.2,7 
Specifically, 1 and 2-year survival of those with LVADs is about 80% and 70% for 
continuous-flow pumps (with recent multi-center retrospective studies citing 45% 
survival to 4 years and mean survival of 4 year survivors to 7.1 years) while transplant 
survival rates are between 85-90% at one year with median survival between 11-13 
years.2,7-9 Thus again, while improvements in LVAD technologies as well as 
understanding of LVAD parameters has overall improved prognosis in patients with 
advanced HF, cardiac transplantation, where possible, remains the best option. 
However, given the complexity of host immunity in response to donor allograft, much is 
yet to be discovered/explained in the context of improving long-term sustainability of 
cardiac allografts.   
 
1.2 Cardiac Allograft Vasculopathy: A Target 
While many advances in cardiac transplantation have been made over the years 
in donor/recipient pairing, immunosuppression, and prevention and treatment of 
nosocomial infections, cardiac allograft vasculopathy (CAV) is among the top three 
causes of death in those who survive past the early post-transplant period (~6 months). 
Nonspecific graft failure, acute rejection, and infection are major causes.10 CAV also 
remains as the most common reason for post-transplant candidates to require re-
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transplant and is identified as a major limiting factor to longer survival in those who 
receive cardiac transplant.10 Angiographic studies have indicated that CAV occurs in 
42% of heart transplant patients at 3 years post-transplant while the more sensitive 
intravascular ultrasonography (IVUS) has pitted estimates of up to 75% at 3 years.11 
While CAV is the best studied in the realm of solid organ transplant and chronic 
allograft changes leading to dysfunction, it is conceptually very similar to other chronic 
post-transplant disorders in allograft vasculopathy (in renal transplantation), 
bronchiolitis obliterans (seen in lung transplantation and in rare situations secondary to 
inflammation), etc…11,12 Thus, CAV has been identified as a target for improving 
outcomes in cardiac transplantation and may further have implications in improving 
transplant outcomes in other fields as well.13 Moreover, understanding the 
underpinnings of the immune-mediated response to allografts could yield valuable 
information outside of the realm of transplant.  
CAV is characterized by concentric fibrous intimal hyperplasia along the 
transplanted epicardial and intramyocardial vessels leading to diffuse stenosis, tissue 
malperfusion, ischemia, and ultimately graft loss.11,14 Changes can be seen as early as 6 
months post-transplant as a mild intimal thickening with potential for mild fibrosis and 
increase in extracellular matrix proteins.11 Due to the nature of CAV being diffuse and 
non-focal as compared to focal atherosclerotic CAD, challenges have emerged in 
diagnosis and treatment. Specifically, traditional angiographic techniques have 
difficulties in picking up focal areas of stenosis (in attempting to compare proximal vs 
distal diameters/pressures) and angioplasty or stents are not able to be implemented as 
there is no focal plaque/atheroma or area to target.11 Furthermore, no medical therapies 
have been identified or developed to ameliorate or halt the progression of CAV.15,16 
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Current therapies are all based on consensus expert opinion (level of evidence C) and 
typically involve modification of the immunosuppressive regimen to include mTOR 
inhibitors rather than anti-metabolites, but much work is ongoing in identifying targets 
and understanding underlying pathophysiology of CAV.17 Thus, there is an urgent need 
to better understand CAV to develop more specific and effective therapies. 
 
1.3 Pathophysiology of CAV 
Early studies on CAV sought to delineate the roles that classical atherosclerotic 
risk factors (hyperlipidemia, diabetes, HTN, etc…) had to play in post-transplant 
coronary arterial disease.18 These early studies found CAV to be clinically distinct from 
CAD due to atherosclerosis, and identified an immunological component to allograft 
vasculopathy/CAV.11,18 Further analysis and studies of pathological samples of CAV 
tissue indicated some potential similarity between CAV and atherosclerotic disease in 
the presence of an immune reaction, but identified differences in the primary antigen 
driver.13,18 In CAV, pathological areas of intimal hyperplasia were found to respect 
suture lines separating host from donor, indicating that the primary driver may be MHC 
incompatibility on luminal endothelial cells as opposed to oxidized LDL in the sub-
endothelium as seen in classic atherosclerosis.13 As such, CAV is often refractory to 
agents aimed at treating CAD, though superimposed effects of atherosclerosis on CAV 
may contribute in certain situations.12,15 Studies performed in immunodeficient mice 
with implanted human coronary artery segments implicated interactions between 
transplanted donor endothelial cells (presenting MHC antigens) and host T cells 
(producing cytokines) as central to CAV.13,19 Specifically, IFN- γ was identified as a key 
mediator of intimal expansion and CAV in this model.13,19 IFN- γ was found to both 
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induce expression of MHC I and II on arterial endothelial cell surfaces (which they are 
minimally expressed to non-expressed in its absence) and lead to arteriosclerotic 
changes in causing intimal expansion.19 Both innate and adaptive immunity were 
identified as contributing to CAV, however, the role of innate immune mediators such as 
natural killer (NK) cells appear to be dependent on the adaptive immune stimulus as, in 
their absence, NK cells alone do not produce CAV-type lesions in transplanted allografts 
in B and T-cell immunodeficient mice (scid mice).14 However, other studies have posited 
a role for innate immune cells in responding to cellular injury in ischemia-reperfusion 
injury and cellular necrosis.12 The role of the innate immune response thus is posited to 
be immunomodulatory in nature.12-14 
Initial observational studies in CAV have indicated a higher risk of developing 
CAV in patients who develop donor specific antibodies (DSA) that are reactive with non-
self MHC molecules expressed by donor endothelial cells.13 Numerous studies have 
correlated higher DSA levels +/- the presence of complement deposition to worse 
outcomes in both survival and/or graft dysfunction due to CAV, potentially establishing 
a relationship between the two and identifying DSA as a potential lead as a therapeutic 
target.17 Immunohistochemical analyses of endomyocardial biopsies and serological 
studies in post-transplant grafts reveal DSA correlates with C4d complement protein 
deposition and worsened outcomes in the presence of both C4d and C3d deposition 
(indicating progression down the complement cascade).14,17,20 From these observations, 
C4d is used as a diagnostic marker for antibody mediated rejection (AMR) on 
endomyocardial biopsy due to the fact that it has a long half-life and is covalently 
bonded to the surface of arterial endothelial cells.20 One accepted pathway by which 
DSA mediates damage to graft vasculature is by binding to foreign MHC antigens on 
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allograft endothelium (with evidence that DSA against class I and class I+II lead to 
worse outcomes)20 and fixation of complement via classical pathway including 
components C1q, C4b, C4d, C3a, C3d, and C5 leading to endothelial cell injury and 
inflammation.21 Studies have shown in vivo that antibodies targeting MHC I can 
provoke graft arteriosclerosis in immunodeficient scid/beige mice potentially indicating 
the primary target of DSA in causing CAV.22 
 
1.4 Current Management Recommendations for CAV 
As above mentioned, no level I recommendations exist for treating AMR.17 
Current therapies for CAV center around the principles of modulation and suppression 
of immune-mediated injury as well as providing supportive therapy for allograft heart 
failure. Traditional immunosuppressive techniques including corticosteroids, 
calcineurin inhibitors (tacrolimus, cyclosporine), mTOR inhibitors (rapamycin, 
sirolimus), and anti-proliferative agents [azathioprine, mycophenolate mofetil (MMF)] 
targeting B and T cells are often included in managing AMR, though systematic studies 
have not been performed studying their efficacy.17 As DSA has emerged as playing a 
central role in invoking chronic allograft rejection, targeting circulating alloantibodies 
via plasmapheresis in combination with other immunosuppression techniques 
(corticosteroids, MMF, cyclophosphamide, etc…) have been implemented in small 
studies indicating some potential efficacy.17,23 Inhibition of circulating alloantibodies via 
IVIg therapy combined again with other immunosuppressive agents has also been 
utilized in small case series with reversal of rejection, but also with high incidence of 
recurrence.17,24 In targeting B cell populations specifically, rituximab, an antibody 
engineered to target B cell surface marker CD20, has been used in small case series as 
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monotherapy as well as salvage therapy with good success and has been found to 
desensitize transplant candidates who have high reactivity against a standard panel of 
HLA subtypes (high panel reactive antibody activity).17,25 As CD20 is not expressed on 
mature plasma cells, the primary alloantibody-producing cell, bortezomib and 
carfilzomib, proteasome inhibitors used in multiple myeloma to deplete plasma cells, 
have been trialed with successes leading to ongoing phase II clinical trials.17,26,27 
Specifically, a study in children receiving renal transplants showed stabilization of grafts 
in C4d positive antibody mediated rejection using bortezomib.28 Larger studies centered 
around using bortezomib in adult renal transplant recipients are ongoing in a Phase II 
trial through the BORTEJECT Study.26 Last, as C4d and complement are also implicated 
in the pathogenesis of CAV, it has been raised as a target as well. Eculizumab, a terminal 
complement inhibitor used in paroxysmal nocturnal hemoglobinuria, has been studied 
in preclinical trials in rats and murine models as successfully able to prevent antibody 
mediated rejection in renal and cardiac transplantation, and one report of utilization of 
eculizumab as salvage therapy was successful in a patient undergoing AMR of a kidney 
transplant, but a larger study in the renal transplant community showed no differences 
after 1 year with eculizumab treatment (though it was found to decrease acute clinical 
antibody-mediated rejection).17,29-31 Again it is noted that current therapies for CAV are 
limited, with medical therapies for CAV limited to switching or increasing 
immunosuppression, and more invasive options including LVADs, PCI (if focal area to 
target), or re-transplantation. 
 
1.5 Complement as an Active Area of Study 
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While the presence of C4d is used clinically as a diagnostic marker for AMR, the 
specific role that complement plays is an area of active study. Complement proteins 
(synthesized in the liver) function in a series of biochemical conversions in the realm of 
innate immunity and, in the setting of DSA fixation, initiate the complement cascade 
culminating in MAC formation via the classical pathway. In this pathway, immune 
complex deposits (IgG or IgM) on the cell surface expose complement binding sites on 
the constant portion (Fc) of the antibody leading to a conformational change of the C1 
complex, in turn activating C4, then C2, to create the C3 convertase (C4b2a).32,33 This, in 
turn, activates C3, leading to creation of the C5 convertase (C4b2a3b) ultimately leading 
to downstream creation of the membrane attack complex (MAC), composed of C5b, C6, 
C7, C8, and polymers of C9.32,33 This terminal complex classically functions via osmotic 
and ion flux, creating pores on the surface of cells leading to rapid influx of water and 
ions.34 However, in nucleated cells and in human cells, numerous protective elements 
exist in order to prevent rapid lytic destruction, a process called homologous 
restriction.35 CD59, a cell surface glycoprotein, regulates terminal complement 
formation by inhibiting C9 (the final complement protein) from assembling the inner 
core of pores that are formed by the MAC complex. It is well studied as being defective 
in paroxysmal nocturnal hematuria, a genetic deficiency of CD55 or decay accelerating 
factor (DAF).34 Presence of ion pumps, though they require energy, can also help to 
stabilize the cell in temporizing and maintaining ion gradients.34 MAC complexes are 
also able to be endocytosed into the cell or ectocytosed via budding.34 While these frank 
lytic effects of MAC are often avoided in nucleated human cells, studies have shown that 
assembly of terminal complement structures on different cell types can lead to various 
signaling changes leading to cell cycle alterations, protein synthesis modifications, and 
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inflammatory changes.34 These studies have indicated that at least three potential 
pathways for signaling exist. First, while ion pumps may maintain membrane integrity, 
rapid calcium influx due to the large extracellular concentration may lead to modulation 
of calcium-binding proteins activating downstream effectors, though some of these 
changes have been observed in a low-extracellular calcium environment indicating 
possible calcium-independent pathways.34 Studies have suggested that the MAC itself 
may interact with G-protein binding motifs as well as TLRs and other signaling 
receptors on the cell surface, though no formal structure or function has been 
elucidated.34,36-38 Finally, the inhibitory CD59 GPI-anchored protein and other GPI 
anchored proteins could also initiate downstream signaling pathways via clustering by 
binding to MAC complexes, though this pathway of MAC-CD59 inducing signaling is 
still being elucidated.34 Thus, while complement’s role in CAV is established as being a 
downstream component of DSA fixation, the specific mechanism by which it acts in both 
CAV as well as more generally in cellular processes is an area of active study. 
 
1.6 Developing a Model and System to Study DSA and Complement 
A challenge associated with studying in vitro and in vivo DSA-mediated 
complement fixation on human endothelial cells is the specificity DSA have for a specific 
HLA molecule (namely those found on the allograft).39 As a surrogate to DSA, polyclonal 
mixtures of antibodies with wide reactivities to a standard panel of HLA antigens, or 
highly reactive (generally >80%) panel reactive antibodies (PRA), have successfully 
been able to mimic the effects of DSA binding to a specific HLA surface molecule.39,40 
These polyclonal antibodies were found to successfully deposit on human endothelial 
cells with fixation of complement proteins potentiating EC-mediated activation of T-
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cells.39 Consistent with the variety of studies regarding terminal complement’s effects on 
nucleated human cells as aforementioned, PRA deposition on endothelial cells led to 
downstream complement fixation and activation on cell surfaces which, instead of 
causing lysis, ultimately induced increased transcription of pro-inflammatory 
mediators.39 These effects reproduced clinical observations where abundant 
complement deposition occurs in target vascular beds that show perivascular immune 
cell infiltrates in the absence of widespread vascular necrolysis.39,41 Moreover, the above 
effects of PRA sera containing entirely human-derived components were not seen in 
other studies incorporating xenogeneic complement components, e.g. antisera, to 
experimentally induce complement activation. 
In using PRA sera to induce terminal complement activation, i.e., MAC assembly, 
three principal mediators of EC activation were identified, namely DSA, anaphylatoxins, 
and MAC.12,39,41 In prior studies involving fractionation and recombination of PRA sera 
and complement-deficient human reference sera, MAC was found to induce EC 
activation, characterized by upregulation of chemokines, cytokines, and adhesion 
molecules.12,39,41 In interrogating the transcriptional and molecular changes associated 
with this response, it was found that the non-canonical NF-kB pathway was being 
activated by MAC.39 Notable findings in these early studies were that the molecular 
changes associated with non-canonical NF-kB signaling were both rapidly inducible 
(changes seen within 30 minutes) and durable (changes lasting up to weeks).39,41 These 
findings were inconsistent with the classically described non-canonical NF-kB signaling 
modality in which changes require ~8 hours in order to be detected.41 Further work 
indicated that PRA-dependent MAC activation of non-canonical NF-kB functioned 
through a novel endosome signaling pathway, utilizing Rab5+ endosomes as opposed to 
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previously held beliefs that signaling occurred from the cell surface due to calcium flux 
as aforementioned being described as one of three potential pathways by which 
complement signaling may occur (calcium-dependent pathway).41 The terminal 
complement MAC were found to be endocytosed via clathrin-mediated endocytosis into 
the cell while localizing to Rab5+ endosomes.41 Rab5 itself is a small GTPase that 
mediates downstream functions through recruiting effector proteins and is a marker of 
early endosomes.42 Ultimately, a Rab5 endosome effector protein ZFYVE21 was 
identified as an inducible effector that serves to modulate the endosome membrane lipid 
content in order to recruit members of the non-canonical NF-kB family in order to 
potentiate signal activation.42 Specifically, ZFYVE21 was found to promote SMURF2-
mediated polyubiquitinylation and proteasome degradation of endosome-associated 
PTEN in order to induce endosome-membrane enrichment of PI(3,4,5)P3 in order to 
recruit activated Akt and NF-kB-inducing kinase (NIK) leading to non-canonical NF-kB 
activation.41,42 In follow-up studies performed subsequent to my thesis studies, the 
Jane-wit lab found that Rab5-associated NIK induced recruitment of inflammasome 
components including NLRP3 and caspase-1 from the ER and cytosol respectively, and 
that apposition of these molecules on Rab5 endosomes caused NLRP3 inflammasome 
activation, a process leading to EC release of IL-1b. 38,43 IL-1b was then found to activate 
canonical NF-kB.38,43 
Thus, the pathway as described currently in the literature functions through the 
following steps: DSA (modeled by PRA) binds to MHC molecules on allograft luminal 
endothelial cell surfaces and affix complement proteins via the classical pathway.41,42 
Terminal complement forms and these MAC are endocytosed into the cell via clathrin-
mediated endocytosis where they co-localize to Rab5+ endosomes.41,42 This, in turn 
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leads to effector protein ZFYVE21 being recruited, activating the ubiquitin ligase 
SMURF2.41,42 SMURF2 marks PTEN in the endosome for degradation, altering the 
endosome membrane content to include higher concentrations of PI(3,4,5)P3 to recruit 
activated Akt which activates NF-kB inducing kinase which leads to downstream NF-kB 
signaling.41,42 ZFYVE21 was detected in a variety of patients with complement-mediated 
disease including transplant rejection, and a bioinformatics search identified a drug 
inhibitor of ZFYVE21, miltefosine, that blocked CAV in a humanized mouse model.42 
 
Interestingly, in interrogating changes associated with this pathway of induction 
of ZFYVE21, MG132, a pan-proteasome inhibitor, was found to induce a similar 
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repertoire of changes associated with PRA-induced MAC deposition on endothelial cell 
surfaces, upregulating ZFYVE21 and inducing NIK downstream in a similar fashion 
suggesting a potential role for proteasomes in initiating this pathogenic pathway.42 
 
1.7 Rab5 and the Rab Protein Family  
Rab proteins form the largest branch of the small GTP-binding proteins, 
commonly referred to as small GTPase proteins, that have an essential role in vesicular 
transport in eukaryotic cells.44-46 Rab proteins structurally form one of at least 5 families 
of small GTP-binding proteins including Raw, Rho, Rab, Sar1/Arf, and Ran, in total 
constituting over 100 members with over 50 Rab proteins having been identified so 
far.45 Identified Rab proteins have been shown to be ubiquitous in eukaryotic cells, 
though there are certain Rab proteins that are cell-type or tissue specific.44 They, along 
with other small GTP-binding proteins, cycle between a GDP-bound off-state and GTP-
bound on-state that is catalyzed by guanine exchange factor (GEF) proteins, however, it 
is noted that Rab proteins have been found to bind to effector proteins to some degree 
even in their “inactive” GDP-bound state.44,46 Rab proteins have been found to cluster in 
membrane compartments on live-cell microscopy, establishing distinct micro-
domains.46 Furthermore, Rab proteins have been found to act through recruitment of 
effector proteins as well as other Rab proteins through specific GEF proteins in order to 
facilitate an organized cascade of downstream events.44,46 Due to their distinct 
localization patterns and specificity for establishing micro-domains, Rab proteins 
initially were thought to function as markers for transport, ensuring vesicles leaving one 
compartment would arrive at a correct destination.44 However, ongoing research has 
identified Rab proteins binding to effector proteins with very diverse functions, 
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implicating them in a larger scheme of intracellular signaling and transport.44,46 Rab5 
specifically has been identified as an early endosomal marker generally composed of 
smaller endosomes that, in a typical progression from early to late endosomes, undergo 
fusion events leading to fewer, larger endosomes with loss of Rab5 and acquisition of 
Rab7, a marker of late endosomes.47 While their role as early endosome markers may be 
diverse, their apparent dynamic, but consistent expression on early endosomes prove to 
be useful as a consistent target in order to identify effector proteins associated with 
these early endosome populations following endocytosis of MAC on endothelial cell 
surfaces. Rab5 effectors including Rabaptin-5 and certain PI3 kinases initiate a myriad 
of downstream functions.44-46,48 ZFYVE21, identified in the studies above, specifically 
and directly bound to Rab5-GTP complexes but not Rab5-GDP and initiated 
inflammatory signaling, thus operationally qualifying this protein as a Rab5 effector.42 
 
1.8 Proteasome Structure and Function 
The proteasome, with known functions in the MAC fixation pathway as targeting 
PTEN for degradation through the ubiquitin-proteasome pathway is regarded as the 
principle proteolytic machinery of the cell. Briefly, proteasomes have a core proteolytic 
element (20S core particle) in a cylindrical orientation that is sandwiched between one 
or two regulatory particles on either side (19S regulatory particle being the most well 
studied).49,50 The regulatory particle is thought to confer a degree of specificity for the 
core proteolytic element, binding to poly-ubiquitylated substrates and regulating the 
opening of the core proteolytic element to degradation of proteins.49,50 Different 
ubiquitin signals and conformations are thought to confer preference to the proteins 
that are allowed passage through the core proteolytic element of proteasomes and in 
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general, polyubiquitin chains have higher affinity compared to monoubiquitinlyated 
proteins.49,50 Proteasomes also play a key role in classically described NF-kB activation 
in both canonical and non-canonical pathways.49,50 Specifically, ubiquitin-mediated 
degradation is required for degradation of the NF-kB inhibitor IkB (generally classified 
in the canonical pathway) and plays a critical role in targeting NF-kB precursors p105 
and p100 (p100 targeting classified in the non-canonical pathway) for proteasomal 
processing into mature forms p50 and p52.51,52 Ubiquitination has also been found to 
play a role in NF-kB protein kinase function independent of proteasome function.51,52 
Thus, both canonical and non-canonical NF-kB activation require proteasome 
degradation of regulatory elements in order to allow for transcriptional activation.49-52 
There have been recent interests in the clinical use of proteasomes inhibitors thought 
previously to be too cytotoxic for systemic use. FDA-approved proteasome inhibitors 
including bortezemib and carfilzomib have been used in numerous clinical settings 
including CAV.14,26,53 
 
1.9 NF-kB Signaling Pathway (Canonical, Non-Canonical, and Non-classical Non-
Canonical) 
Nuclear factor found near the kappa segment of B cells (NF-kB) was initially 
discovered by the Baltimore lab as a rapidly inducible transcription factor since found to 
have broad implications in a diverse set of cellular responses ranging from inflammation 
to oncogenesis. The NF-kB signaling pathway effector proteins consist of 5 family 
members p50, p52, Rel A (p65), Rel B, and c-Rel which all function through binding to 
promotor/enhancer sites of target genes regulating transcription by recruitment of 
activator and repressor proteins.54-57 At baseline, these effector proteins reside in the 
16 of 53 
 
cytoplasm in inactive forms, bound to above-mentioned inhibitory IkB proteins.54-57 
Upon activation, the IkB protein is marked for degradation by proteasomes often after 
phosphorylation by a IkB kinase complex and the active NF-kB proteins heterodimerize 
and translocate to the nucleus to modulate expression.54-57 
In studying activation of the NF-kB pathway, there classically has been a 
distinction between the “canonical” and “non-canonical” pathways based on the triggers 
as well as pathway mediators.54-57 In the canonical NF-kB pathway, microbial products 
activating toll-like receptors (TLRs) or pro-inflammatory cytokines like TNF-⍺ or IL-1 
leads to activation of IkB kinase complexes by TRAF/RIP complexes inducing 
phosphorylation and degradation of inhibitory IkB⍺ releasing NF-kB dimers which 
translocate to the nucleus.54-57 In the non-canonical or alternative pathway (described 
mostly in lymph-organogenesis as well as B-cell activation), TNF-family cytokines 
(excluding TNF-⍺), CD40L, RANKL and B-cell activating factor leads to activation of 
IkB kinase complexes through TRAFs and NF-kB-inducing kinase (NIK) leading to 
proteasomal processing of p100 to p52.54-57 Classically in non-canonical NF-kB 
signaling, NIK levels increase slowly over several hours and are correlated with 
degradation of TRAF3 (through ubiquitination).39,41,54-57 What has been observed in 
DSA-mediated complement signaling on endothelial cells, however, is that there is a 
rapid induction of NIK that is not correlated with TRAF3 degradation and the levels are 
durably elevated for weeks after PRA treatment indicating a non-classical model of non-
canonical NF-kB induction.39,41 As previously described, phosphorylated Akt upstream 
of NIK plays a central role in this rapid induction and the ZFYVE21 pathway modifies 
the Rab5 endosomal lipid landscape (via PTEN) in order for phosphorylated Akt to be 
recruited.39,41,42 
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1.10 TGF-ß Signaling Pathway and SMURF2 
The TGF-ß family of proteins are nearly ubiquitously expressed in all cell types, 
including endothelial cells, and play key roles in growth, differentiation, and tissue 
morphogenesis.58 TGF-ß signaling occurs primarily through surface complexes of Type I 
and Type II receptors and their downstream effector Smad proteins that exist in three 
subgroups encompassing R-Smads, Smad4 in vertebrates, and I-Smads.58,59 Notably, 
TGF-ßRI is ubiquitously expressed on cells.60 The signaling cascade is described as the 
following: ligand binding or a type III receptor presentation leads to TGF-ßRII (Type II 
receptor) that is constitutively active recruiting TGF-ßRI (Type I receptor) to form 
heterodimers.58,59 Following complex formation between type I and II receptors, the 
active TGF-ßRI phosphorylates and activates downstream Smad2 and Smad3 which 
ultimately oligomerize with a common Smad4 to translocate to the nucleus to regulate 
expression of target genes.58,59 Again, the roles of TGF-ß are complex and varied, and its 
role in novel signaling pathways are still being elucidated, though canonically, TGF-ß 
signaling has been shown to mediate anti-inflammatory effects in T cells, B cells, and 
macrophages, with the role of this signaling pathway in CAV unknown.61 
As previously described above, proteomic analyses of FACS-sorted MAC+Rab5+ 
endosomes showed a reduction in spectral counts for PTEN, a PI(3,4,5)P3 phosphatase 
that functionally acts as an Akt inhibitor.42 Prior studies showed that the MAC induced 
loss of PTEN from MAC+Rab5+ endosomes and that PTEN was inducibly 
ubiquitinylated and targeted by proteasomes for degradation.42 To identify E3 ubiquitin 
ligases that could mediate this process, we looked at the literature for other proteins that 
could ubiquitinylate PTEN and found that 2 of these proteins were in the NEDD4 
family, consisting of 9 proteins.42,62-66 Of these, the Jane-wit lab identified SMURF2 as a 
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mediator of PTEN ubiquitinylation.42 SMURF2, or Smad ubiquitin regulatory factor 2, is 
a type E3 ubiquitin ligase located primarily in the nucleus that has been best studied in 
its role as a regulator of the TGB-ß signaling pathway.67-69 Classically, SMURF2, similar 
to its related isoform, SMURF1, has been characterized as a negative regulator of TGF-ß, 
translocating out of the nucleus in response to TGF-ß receptor activation, binding to I-
Smads (inhibitory Smads) to ubiquitinate TGF-ß type I receptors leading to their 
proteasomal degradation to attenuate the TGF-ß signal.67-69 However, SMURF2 has 
been found to play a role in numerous other capacities including tissue homeostasis, 
genomic stability, and even in tumorigenesis (as opposed to its classically studied and 
accepted role in tumor suppression).67-69 In the DSA-induced complement signaling 
pathway, SMURF2 retains its ubiquitin ligase role in ubiquitinating PTEN on the Rab5 
endosomal surface, leading to its degradation in order to influence the endosomal lipid 
content for downstream recruitment of effectors.42 
 
2. Statement of Purpose: 
 
As highlighted above, a potential link between antibody-mediated complement 
fixation has been established with CAV through the MAC-induced ZFYVE21 signaling 
pathway leading to downstream non-canonical NF-kB induction. To understand the 
nature by which this novel pathway of non-canonical NF-kB is activated, the focus turns 
to the means by which the downstream pro-inflammatory signaling proteins are 
induced on the Rab5+ endosomal membrane. 
In terms of protein induction, two general pathways can be considered: 
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A. “Slow pathway” involving 
transcription and translation 
leading to gradual protein 
accumulation in hours. 
B. “Rapid pathway” involving protein 
activation (phosphorylation by 
kinases, cleavage, etc…) or rescue 
from basal degradation (basally 
transcribed, translated, and 
ubiquitinated for degradation by 
proteasomes under homeostatic 
conditions). 
 
A notable finding in the early studies of the DSA-mediated complement signaling 
pathway was the rapid nature (within 30 minutes) by which the NF-kB pro-
inflammatory signaling proteins were induced. Furthermore, prior to induction, these 
proteins were not found in either their active or inactive states. Thus, it is hypothesized 
that these stress-related proteins are basally ubiquitinated and degraded by 
proteasomes while in homeostatic conditions, and in response to stressors like 
complement deposition, are rescued from proteasomes to rapidly accumulate to 
perform their effector function. As noted in the literature described above, proteasomes 
are known to have some degree of specificity as conferred through their lid element, and 
the pan-proteasome inhibitor MG132 was found to induce similar changes as DSA-
mediated complement signaling. 
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After induction or rescue of these stress-related proteins, it is posited that the 
proteins are recruited or localized to a common signaling platform of Rab5+ endosomes 
where they are stabilized and positioned in proximity to each other to perform their 
downstream signaling function. Rab5+ endosomes were found to be a centralized 
location in which the initial components of DSA-mediated complement signaling were 
found. 
The initial aim of my study was to identify other proteasome-mediated molecules 
like ZFYVE21 that were recruited to Rab5 endosomes to activate NF-kB. During the 
course of my studies, I unexpectedly uncovered a role for TGF-ß signaling in CAV, and I 
redirected my study to understand how this pathway became activated and how it 




Antibody-induced complement activation post-translationally sequesters pro-
inflammatory signaling proteins on Rab5+ endosomes following a two-step model: 
1. Inhibition of a proteasome population leads to rapid up-regulation of 
inflammation-related proteins. 
2. After rescue, inflammatory proteins are recruited to Rab5 endosomes in 




*Student independently performed 
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**Student performed parts of experiment 
***Performed by other members of lab 
 
Endothelial Cell Culture and Treatment*: Human umbilical vein endothelial cells 
(HUVEC) obtained as de-identified tissue discarded from the Department of Obstetrics 
and Gynecology at Yale New Haven Hospital were plated in gelatin-coated flat bottom 
culture flasks, dishes, or multi-well plates (BD Biosciences, San Jose, CA) with 
Endothelial Cell Growth Medium-2 (EGM-2MV) containing 20% FBS, hydrocortisone, 
hFGF-B, VEGF, IGF-1, ascorbic acid, hEGF, and GA-1000 (Lonza Bioscience). Cells 
were serially cultured at 37°C with 5% CO2. All experiments in this manuscript were 
performed with cells at passage levels 2-6 at which point such cultures are free of 
contaminating leukocytes and uniformly express EC markers. To split the cells and/or 
plate for culture, trypsin-EDTA (0.25%) was used to dissociate the adherent cells from 
the vessel. Cells were trypsinized for no more than 60 seconds. Cells were plated at an 
ideal concentration of 10,000 cells in 200 µl. Discarded high-titer PRA sera were 
obtained as de-identified samples from Yale-New Haven Hospital's tissue typing 
laboratory and showed >80% reactivity to either HLA class I and/or II antigens. PRA 
sera underwent endotoxin testing according to manufacturer!s specifications (Sigma) 
and human viral pathogen testing under h-IMPACT testing protocols (IDEXX RADIL, 
Columbia, MO). Prior to PRA treatment or in control groups for PRA treatment, HUVEC 
were pre-treated for 48-72 hours with IFN- γ (50ng/mL, Invitrogen, Grand Island, NY) 
in EGM-2 medium prior to addition of a 1:10 dilution of a PRA positive serum in gelatin 
veronal buffer (Sigma, St. Louis, MO) for the indicated times. For MG132 treatment, 
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MG132 (25 µM, Selleck Chemicals) was added to EGM2 media for the indicated times at 
the indicated concentration of 1:1000. 
 
Western Blotting/Analysis*: Expression levels of intracellular proteins were 
quantified by western blotting. To do so, EC monolayers grown to 80-90% confluence 
from C6 or C12 wells (BD Biosciences, San Jose, CA) were washed in ice cold PBS three 
times and lysed in RIPA buffer (Sigma). Samples were then mixed with Laemmli's 
sample buffer, heated at 95°C for 10 minutes, and loaded at 30µg per lane. After 
electrophoretic resolution, samples were transferred onto a PVDF membrane (EMD 
Millipore) for two hours at room temperature. Membranes were blocked with 5% BSA 
and primary antibody was added at 1:1000 dilution overnight at 4°C while rocking 
gently. Primary antibodies were all used at 1:1000 dilution and included ZFYVE21 
(Novus Biologicals), SMURF2 (Cell Signaling Technology), NIK (Cell Signaling), active 
Rab5 (NewEast Biosciences), Rab5 (Santa Cruz Biotechnology), TGF-ßRII (R&D), 
smad2 (R&D), smad3 (R&D), p-smad2/3 (R&D), TGF-ßRI (R&D), PSME4 (Abcam), 
PSMD3 (Abcam), KIAA0368 (Abcam), PSME1 (Bethyl), PSMF1 (Bethyl), PSMB8 
(Bethyl), PSMA2 (Bethyl), PSMC2 (Bethyl), Rubicon (Cell Signal), and β-actin (Sigma). 
Anti-mouse and anti-rabbit horse radish peroxidase (HRP)-conjugated antibodies 
(ThermoScientific, Waltham, MA) were then added at room temperature for one hour at 
a dilution of 1:1000 and bound HRP was visualized using chemiluminescent developing 
of probed membranes on X-ray film (Denville Scientific, Metuchen, NJ) as per 
manufacturer!s specifications (SuperSignal Pico West, Pierce, Junction City, OR). 
Densitometry was performed using NIH Image J software (Bethesda, MD). 
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Co-Immunoprecipitation**: For co-IP experiments, 20 µL protein A/G beads 
(ThermoFisher) were incubated with 10 µL Rab5 antibody, PMSC2 antibody, or PSMA2 
antibody at 4 °C overnight. Rab5 antibody (1 µg, abcam) and protein lysates (10ug) were 
incubated at 4 °C overnight (Pierce). Antibody-conjugated beads. The next day, 
antibody-bound lysates were mixed with agarose protein A/G beads. The beads were 
washed and resuspended at a volume of 32 µL using RIPA buffer (Cell Signaling). For 
western blotting, following the incubations, Laemli!s buffer (12 µL) and 1 mM 
dithiothreitol (6 µL) were then added to samples, heated for 95 °C for 13 min, and 
subjected to western blotting. Antibodies used for western blotting were all used at 
1:1000 dilution as described above. For proteomics analysis, after elution of protein, 
labeled samples were sent to Yale Proteomics lab (The Mass Spectrometry (MS) & 
Proteomics Resource of the W.M. Keck Foundation Biotechnology Resource 
Laboratory). 
 
Transfection of Rab5 Constructs***: Rab5-GFP WT and DN constructs were gifts 
from Dr. Michael Simons (Yale University School of Medicine, New Haven, CT). To 
transfect plasmids, ECs at 60– 70% confluency in 24-well dishes were pretreated with 
IFN-γ as above for 48 h, followed by transfection of dynamin or Rab5 WT and DN 
constructs using lipofectomy. Then 500 ng of each construct was mixed with 0.4 µL of 
PLUS reagent (Invitrogen) in 200 µL/well of Opti-MEM for 5 min at room temperature, 
followed by the addition of 1.5 µL of Lipofectamine 2000 (In- vitrogen) for 30 min at 
room temperature. This mixture was added to cultured HUVECs at 37 °C for 8 h, 
followed by washing and buffer exchange with EGM2-MV medium. Using this protocol, 
∼30–50% of ECs remained viable for analysis. The transfection efficiency calculated 
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using flow cytometry measuring GFP fluorescence was typically >45%. GFP+ ECs were 
then sorted and replated to yield homogeneous cultures carrying each respective 
construct. 
 
siRNA transfection of EC**: HUVECs were pretreated with IFN-γ for 48hrs prior to 
siRNA transfection. siRNA (Dharmacon, Waltham, MA) targeting PSMC2 or non-
targeting siRNA (target sequence UAA CGA CGC GAC GAC GUA A) were purchased 
commercially (Dharmacon) and transfected into HUVECs at ~60–70% confluency in 
24-well plates (BD Falcon). siRNAs were diluted at 40 nM concentration in Opti-Mem 
culture media (Gibco) and mixed at equal volume with RNAiMax transfection reagent 
(Invitrogen) diluted 1:50 in Opti-Mem for 45 min at room temperature. This mixture 
was then added to HUVEC cultures at 37 °C for 6 h prior to washing and buffer 
exchange with EGM2-MV. Cells were then analyzed by western blots 72 h after 
transfection. 
 
Statistical methods*: Statistical analyses were performed using the computer 
software “Origin” (Origin, Northampton, MA). Absolute numbers and percentages of 
vesicles were analyzed by Student!s t test and Chi-squared analyses, respectively. p 
values < 0.05 were considered statistically significant. Multiple comparison analyses 
were performed using analysis of variance. Standard deviations are reported throughout 
the text. References using the ImageJ image analysis software (Bethesda, MD) with the 
Just Another Colocalisation Plugin (JACoP). 
 
 




5.1 Proteomics Screen to Identify Rab5+ Endosome-Sequestered Proteins 
Given the central role that the Rab5+ early endosome population plays in the 
DSA-mediated complement signaling pathway, our focus initially centered on searching 
for and identifying pro-inflammatory signaling proteins that are post-translationally 
sequestered on Rab5+ endosomes in response to DSA. As Rab5 is ubiquitous on these 
endosomes, our strategy was to use Rab5 to perform co-immunoprecipitation to pull 
down endosomal populations of interest, elute peptides from said endosomes, and 
perform proteomic analysis to interrogate the effector proteins that are recruited to 
these endosomes (Figure 3). Specifically, we cultured five groups of human umbilical 
vein endothelial cells (HUVEC) with experimental Rab5 construct groups and treatment 
groups. The five groups were Rab5DN (constitutively inactive) control, Rab5Q79L 
(constitutively active) control, Rab5Q79L (constitutively active) with MG132 pan-
proteasome inhibitor, Rab5Q79L (constitutively active) with PRA treatment for 4 hours, 
Rab5WT (wild type) with PRA treatment. Both Rab5DN and Rab5Q79L groups were 
used as controls to identify the 
spectrum of proteins normally 
recruited to Rab5 endosomes under 
homeostatic conditions. The 
Rab5Q79L group with MG132 was 
used in order to screen for proteins 
that are nonspecifically rescued 
from proteasomal degradation and 
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recruited to active Rab5 endosomes. The Rab5Q79L group with PRA treatment served to 
comb through pro-inflammatory proteins rescued from degradation and recruited to 
active Rab5 endosomes. Last, the Rab5WT group with PRA treatment mimics the 
pathophysiological response to DSA binding onto allograft transplant vessels and to the 
DSA-mediated complement fixation pathway. 
From this proteomics screen, 1956 unique proteins on Rab5 endosomes were 
identified and categorized based on their known associated pathways (Figure 4). 
Notably, 494 unique proteins were found to be in common between all 5 groups. The 
Rab5WT-PRA group was found to have 175 unique proteins and shared 67 proteins with 
the inactive Rab5 (Rab5-GDP) control group and 5 proteins with the active Rab5 (Rab5-
GTP) control group (Figure 4a). In focusing on the proteins unique to the PRA-Rab5WT 
group that were not found in the control Rab5 groups, many of the proteins 
differentially unregulated and recruited on Rab5 endosomes fell into families of general 
inflammatory mediators such as in the Type 1 IFN response family, IL-12 signaling 
family, and IL-6 signaling family (Figure 4b). Other proteins were found to be related to 
vesicle trafficking pathways such as clathrin-mediated endocytosis signaling and 
secretory vesicle proteins, indicating a likely increase in vesicle transport in the PRA-
Rab5WT group (Figure 4b). The top family that was differentially unregulated and 
recruited in the PRA-Rab5WT group compared to control groups, however, was the 
SMAD-Associated Signal Activation proteins, or proteins associated with the TGF-ß 
pathway (Figure 4b). Alongside this strong positive differential presence of TGF-ß 
family proteins on Rab5 endosomes in DSA-induced complement fixation states, it is 
again noted from prior literature (above-mentioned) that the DSA-mediated 
complement pathway utilizes SMURF2, a known TGF-ß signaling protein, suggesting a 
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link between these two seemingly divergent pathways. Preliminary analysis performed 
from the proteomics screen furthermore confirmed increased amounts of TGF-ß family 
proteins on Rab5 endosomes in the PRA-Rab5WT group compared to control groups 
such as TGF-ß1, TGF-ß2, TGF-ßR2, BMP-R2, and SMAD proteins (Figure 4c). 
 
As the TGF-ß family of proteins has been identified as a potential target of 
interest that may serve effector functions in the DSA-mediated complement fixation 
pathway, our aim moving forward focuses on showing that TGF-ß proteins follow the 
two-step model described above of first being rescued from basal degradation by a 
proteasome population and second being recruited to Rab5 endosomes to perform their 
effector function. 
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5.2 TGF-ß Signaling Components are Induced Following Antibody-Induced 
Complement Fixation 
In order to confirm the initial 
results obtained by the proteomics 
screen that DSA-mediated 
complement fixation leads to 
induction of TGF-ß components, 
western blots of serial co-IPs of 
Rab5 were performed following 
PRA treatment of endothelial cells 
at 0, 5, 15, and 30 minutes of both 
previously described antibody-
induced complement signaling 
pathway mediators such as 
ZFYVE21, SMURF2, and NIK, as 
well as proximal TGF-ß pathway 
mediators including TGF-ßR2, 
smad2, smad3, and the 
phosphorylated smad 2/3 complex 
(Figure 5). 
In confirming prior studies describing DSA-induced complement signaling, 
ZFYVE21 was found to be up-regulated on Rab5 endosomes within 5 minutes, leading to 
subsequent increases in both SMURF2 as well as NIK, again displaying previously 
described rapid induction of non-canonical NF-kB (Figure 5). Furthermore, proximal 
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signaling effector proteins in the TGF-ß pathway including TGF-ßRII, smad2, smad3, 
and the activated heterodimerized phosphorylated smad2/3 complex were all found to 
be induced in a similar rapid timeframe as the antibody-induced complement signaling 
pathway with sustained increase up to 30 minutes (Figure 5). Thus, antibody-induced 
complement fixation is seen to lead to rapid induction of TGF-ß proximal effector 
proteins in a similar timeframe as induction of the ZFYVE21-mediated pathway 
activating non-canonical NF-kB through NIK. 
In the case of antibody-induced complement fixation leading to up-regulation of 
ZFYVE21 and downstream non-canonical NF-kB induction, a pan-proteasome inhibitor 
MG132 was previously found to induce similar rescue of ZFYVE21 and associated 
proteins leading to the hypothesis that there is basal degradation of antibody-induced 
complement signaling pathway effectors by proteasomes. To test whether TGF-ß 
proximal effector proteins are similarly degraded at baseline by proteasomes, we 
performed similar experiments introducing MG132 at the same concentration to 
endothelial cells and subsequently 
performed serial western blots of proximal 
TGF-ß pathway effector proteins (Figure 
6). Again, similar to previously described 
induction of ZFYVE21 and downstream 
proteins, TGF-ßRII and smad2 were found 
to be induced in endothelial cells within 30 
minutes of treatment with MG132 and 
sustained to at least 4 hours (Figure 6). 
TGF-ßRI was found to be ubiquitously 
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expressed as previously described in the literature and minimally affected by MG132 
treatment (Figure 6). Thus, it appears that similar to ZFYVE21 and other antibody-
mediated complement signaling effectors described previously in the literature, TGF-ß 
effector proteins are similarly degraded at baseline by proteasomes and, in the presence 
of antibody-mediated complement fixation, are rescued from degradation. 
 
5.3 Downstream TGF-ß Signaling Components are Post-Translationally Rescued from 
Proteasomal Degradation and Proximal TGF-ßR2 is Post-Translationally Stabilized on 
Activated Rab5 Endosomes 
To further interrogate the dynamics of 
TGF-ß superfamily proteins after post-
translational rescue from proteasomal 
degradation and their relationship to Rab5 
endosomes, we transduced HUVEC cells with 
two different Rab5 constructs: Rab5 S43N 
(dominant negative) and Rab5 Q79L 
(constitutively active) (Figure 7). After 
establishing these groups, we treated each with 
pan-proteasome inhibitor MG132 which binds 
to the 20S catalytic core, and performed serial 
western blots over time (0, 1, 2, and 4 hours) 
for ZFYVE21 (as an internal control) and 
members of the TGF-ß superfamily of proteins including TGF-ßRII, smad2 and smad3 
(Figure 7). 
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As can be seen in both of the groups, the pan-proteasome inhibitor MG132 
induced post-translational rescue of the downstream TGF-ß signaling components 
SMAD2 and SMAD3 beginning at 1 hour after treatment sustained to 4 hours after 
treatment (Figure 7). However, levels of both ZFYVE21 and TGF-ßRII were not seen to 
be increased in the Rab5 dominant negative group treated with MG132 alone (Figure 7). 
In comparison, in the constitutively active Rab579L group, both ZFVYE21 and TGF-ßRII 
were found to be increased (Figure 7). From this, it can be deduced that while TGF-ßR2 
and ZFYVE21 are both post-translationally rescued from proteasome degradation by a 
pan-proteasome inhibitor, there may be a secondary requirement of being translocated 
to Rab5-GTP or active Rab5 endosomes in order for them to be stabilized. 
This combined with Figure 6 shows again the integral role that proteasomes 
appear to play in the signaling modality that is induced by antibody-mediated 
complement fixation. 
 
5.4 The PA200 Proteasome Population is Selectively Inactivated by Antibody-Induced 
Complement Activation 
As discussed above in literature review, proteasomes are posited to have some 
degree of specificity in the proteins that they target. Furthermore, it is noted in the 
proteomics analysis performed at the outset that the proteins discovered in the MG132-
Rab5-GTP group (pan-proteasome inhibitor and constitutively active Rab5) did not 
entirely overlap with the PRA-Rab5 group (Figure 4a, 4c) suggesting that a specific 
proteasome population is selectively inactivated in the presence of antibody-induced 
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complement fixation. In order to 
interrogate whether there is 
selective inactivation of 
proteasome populations by 
antibody-induced complement 
activation, cells treated with PRA 
underwent serial co-IP over time 
(0, 5, 15, 30, and 60 minutes) 
using a common core proteolytic 
element PSMA2, and western 
blots were performed to identify 
specific proteasome populations 
of interest (Figure 8). Co-IP was 
performed using the common 
core component PSMA2 in order 
to ensure internal validity by normalizing the levels of proteasomes sampled over time. 
From this, it is noted that two components that confer specificity to the PA200 
proteasome population, PSME4 in row 1 (encoding the specific PA200 molecule that 
binds to and affects proteasome function) and PSMD3 in row 2 (a regulatory 26S 
subunit on the cap of proteasomes), are selectively inactivated within 5 minutes of PRA 
treatment, while levels of other proteasome population lid elements in rows 3-7 are 
stable up to one hour following PRA treatment (Figure 8). This finding serves to suggest 
that antibody-induced complement activation specifically targets the PA200 population. 
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5.5 The PA200 Proteasome Basally Degrades ZFYVE21 Effector Proteins and TGF-ß 
Signaling Molecules 
While antibody-induced complement signaling appears to specifically target the 
PA200 proteasome population for degradation, attention then was turned to whether 
the PA200 proteasome population 
indeed targets and degrades antibody-
mediated complement signaling 
pathway mediators such as previously 
described ZFYVE21 mediators as well as 
our newly found TGF-ß superfamily 
proteins. 
In order to confirm that the 
PA200 proteasome targets components 
induced by antibody-mediated 
complement fixation, we knocked down 
a PA200 proteasome lid element via 
siRNA of the PSMC2 gene in the 
presence and absence of PRA and 
performed western blots of ZFYVE21 
mediators and proximal TGF-ß pathway 
mediators (Figure 9).  In order to 
confirm knock-down of PSMC2 with the 
siRNA, PSMC2 was blotted in Row 8 
indicating partial, but not complete 
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knock-down in the PSMC2 siRNA groups as compared to the control siRNA groups 
(Figure 9). When comparing lanes 1 and 2 in the non-PRA-treated group, it is observed 
that ZFYVE21 and its downstream effectors as well as TGF-ß pathway effectors all 
increase in the presence of the proteasome lid knockdown group compared to the 
control siRNA group (Figure 9). A similar increase can be seen when one compares 
lanes 3 and 4 in the PRA-treated groups (Figure 9). Specifically, ZFYVE21, SMURF2, 
NIK, and Rubicon in the ZFYVE21 pathway induced by antibody-mediated complement 
fixation and TGF-ßRII, smad2, and smad3 in the TGF-ß superfamily of proteins were 
found to increase in the proteasome knockdown group compared to controls in both 
physiological and PRA-treated settings (Figure 9). It is also noted that when one 
compares the control groups to the PRA groups, there were increases in proteins from 
both the ZFYVE21 pathway as well as TGF-ß pathway (specifically by comparing lanes 1 
and 3 and 2 and 4) (Figure 9). 
Last, of note is that the level of PSMC2 appears to have been unaffected by PRA 
treatment, potentially indicating the lid component of the PA200 proteasome remains 
intact, but unable to associate with the PA200 proteasome or perform effector function 
(Figure 9). The idea that these lid components dissociate from the core proteasome 
element is supported from data shown in Figure 8 as, following PRA treatment, the lid 
elements PSME4 and PSMD3 are no longer found to be pulled down with core element 
PSMA2 in co-IP studies. 
 
5.6 PA200 Proteasome Components are Recruited to Rab5+ Endosomes 
In further exploring the PA200 proteasome dynamics in relation to the Rab5 
endosomes where antibody-mediated complement signaling proteins appear to localize, 
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attention was turned to whether or not proteasome components are recruited to Rab5 
endosomes at baseline or whether they translocate following antibody-mediated 
complement fixation. From the proteomics screen, when comparing constitutively active 
Rab5 endosomes (Rab5-GTP), constitutively active Rab5 endosomes with MG132 pan-
proteasome inhibitor treatment, and wild-type Rab5 treated with PRA, numerous 
proteasome components are seen to be upregulated on Rab5 endosomes in endothelial 
cells treated with PRA compared to cells with constitutively active Rab5 or with 
constitutively active Rab5 with proteasome inhibitor MG132 (Figure 10a). This suggests 
that antibody-induced complement fixation differentially recruits proteasome elements 
onto Rab5 endosomes. However, as noted again in Figure 8, specific components of the 
PA200 proteasome are not found to be associated with functional core PSMA2 
proteasome components following PRA treatment, indicating that apparent recruitment 
of lid components does not equate to proteasome function. 
Furthermore, when performing serial co-IP of the proteasome lid component 
PSMC2 and blotting for signaling proteins induced by antibody-induced complement 
fixation, it is seen that over time there are increases in Rab5, TGF-ßRII, and ZFYVE21 
after PRA treatment (Figure 10b). Increase in Rab5 co-localization with PSMC2 after 
PRA treatment shown in row 1 once again points towards recruitment of the PSMC2 lid 
component to these Rab5 endosomes and increase in TGF-ßRII and ZFYVE21 reaffirms 
previously described co-localization on the Rab5 endosome in rows 2 and 3 (Figure 
10b). Presence to some degree of TGF-ßRII and ZFYVE21 at time 0 in rows 2 and 3 with 
PSMC2 could further be indicative of these proteins bound to PSMC2 destined for 
degradation, but prior to entering the proteasome core element to be fully degraded 
(Figure 10b). 




The present work aims to establish the TGF-ß superfamily of proteins as a 
potential component in the pathogenesis of cardiac allograft vasculopathy induced by 
DSA-mediated complement fixation as well as study more generally the mechanism by 
which antibody-mediated complement fixation leads to rapid signaling changes, such as 
leading to activation of non-canonical NF-kB (and subsequently canonical) as previously 
described in the ZFYVE21 pathway.42 
As ZFYVE21 and its downstream mediators were found to localize to Rab5 
endosomes following antibody-mediated complement fixation, we hypothesized initially 
that the previously described landscape of protein makeup on Rab5 endosomes in 
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homeostatic conditions differed from the proteins recruited to Rab5 endosomes 
following a stressor such as antibody-mediated complement fixation. Thus, in order to 
elucidate or search for those differences, we grouped HUVEC cells into five different 
conditions/treatments reflecting homeostatic vs non-homeostatic conditions and 
performed co-IPs of Rab5 in order to capture early Rab5 endosomes and sent the eluted 
peptides of the endosomes for proteomic analysis. The five groups we chose included 
HUVEC cells with constitutively inactive Rab5 under homeostatic conditions, 
constitutively active Rab5 under homeostatic conditions, constitutively active Rab5 with 
pan-proteasome inhibitor MG132, constitutive active Rab5 with PRA treatment, and a 
wild-type Rab5 with PRA treatment. Both the constitutively inactive and active Rab5 
groups under homeostatic conditions served as controls in order to sample all the 
proteins that would be recruited to early Rab5 endosomes. The MG132 group with 
constitutively active Rab5 was meant to sample all the proteins that are rescued from 
proteasomal degradation that have peptide motifs that would allow them to be 
nonspecifically recruited to active Rab5 endosomes. The constitutively active Rab5 
endosomes treated with PRA were meant to understand the specific sub-population of 
proteins that are induced by antibody-mediated complement fixation and recruited to 
active Rab5 endosomes and, through comparison with the Rab5 wild-type group treated 
with PRA, one could deduce the proteins that are recruited to inactive Rab5 endosomes 
treated with PRA. Finally, the wild-type Rab5 group with PRA treatment served to 
closely mimic the proteins and signaling events occurring in antibody-mediated 
complement fixation seen as one component causing CAV. 
Classically, rigorous experimental design would necessitate the presence of a 
wild-type Rab5 group under homeostatic conditions instead of a constitutively active 
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and inactive Rab5 under homeostatic conditions in order to prevent the possibility of 
confounding variables, however, the spectrum of proteins recruited to constitutively 
active and inactive Rab5 endosomes under homeostatic conditions was seen as more 
informative as a dual-control variable given the ability to sample all proteins in 
homeostatic conditions that would be recruited to Rab5 endosomes, and would give 
more insight down the road in terms of proteins that are differentially recruited in GTP 
and GDP states. One must recognize, however, the potential confounding variable the 
process of transfection of the HUVEC cells with gene constructs may cause in 
inadvertently altering the landscape of signaling events. While there is no specific 
literature discussing the role of transfection affecting the landscape of Rab5 endosomes, 
transfection, whether it be viral (biological) or chemical has been theoretically proposed 
to affect the cell.70,71 However, in the case of this study, all further analysis after the 
proteomics screen was done with native HUVEC cells with or without PRA treatment. 
Thus, there is greatest risk of a beta error, or missed signaling pathway, from this 
proteomics screen as there may be proteins recruited to Rab5 endosomes in the control 
groups that otherwise would not be without transfection. 
Through this proteomics screen, we identified the TGF-ß superfamily of proteins 
as being differentially upregulated on Rab5 endosomes as compared to homeostatic 
conditions, pointing towards its role as an antibody-mediated complement pathway 
mediator. As previously stated, the TGF-ß superfamily protein SMURF2 was previously 
identified as playing a role in the ZFYVE21 pathway, hinting at the role that the TGF-ß 
pathway may play in the greater signaling changes induced by antibody-mediated 
complement.42 Furthermore, it is well described in the literature that proximal TGF-ß 
receptors localize to and signal from early endosomes following clathrin-mediated 
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endocytosis and a less clearly described lipid/caveolae-mediated endocytosis.72-75 Thus, 
we decided to move forward with studying the TGF-ß superfamily of proteins in its 
relation to antibody-mediated complement signaling. 
In order to confirm the upregulation of TGF-ß component proteins on Rab5 
endosomes following antibody-mediated complement fixation, western blots of co-IP of 
Rab5 showed rapid induction of TGF-ß component proteins on Rab5 endosomes similar 
to both previously described ZFYVE21 pathway mediators as well as repeat ZFYVE21 
blots performed for the sake of internal validity.42 It was observed that within 5 minutes, 
TGF-ß signaling components were upregulated on Rab5 endosomes. Furthermore, in 
returning to our original hypothesis, these TGF-ß signaling components seem to follow a 
similar “rapid induction” that would not be expected in the case of differential gene 
expression leading to transcription and translation. Thus, in order to test the hypothesis 
that TGF-ß signaling components follow closely with ZFYVE21 pathway mediators as 
being rescued from a baseline proteasomal degradation, we treated HUVEC cells with 
MG132, a pan-proteasome inhibitor in order to study whether or not these TGF-ß 
mediators were basally transcribed, recruited to proteasomes, and degraded. Serial 
western blots over time after MG132 treatment was notable for upregulation of TGF-ß 
signaling components more firmly implying a role for proteasomes in the antibody-
mediated complement signaling as well as partially satisfying the first posit of our initial 
hypothesis that inhibition of proteasomes leads to rapid upregulation of inflammation-
related proteins. 
Next, we sought to test the conditions in which antibody-mediated pathway 
proteins are recruited to Rab5 endosomes. We introduced pan-proteasome inhibitor 
MG132 to cells with constitutively inactive Rab5 and constitutively active Rab5. From 
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this, we found that the level of downstream smad2/3 in the TGF-ß signaling pathway 
were all rescued from basal degradation in both groups irrespective of Rab5 status. 
However, ZFYVE21 and TGF-ßRII were both only found to be upregulated in the 
constitutively active Rab5 group (Rab5-GTP), implying a prerequisite Rab5-GTP state 
for these proteins to be stabilized. The levels of smad2/3 being elevated irrespective of 
Rab5 endosome status is not surprising given they are not classically described as 
signaling from endosomes, whereas TGF-ßRII, being a membrane protein receptor, is 
described as functioning from an endosomal base, similar to ZFYVE21.42,72-75 
As non-specific inhibition of proteasomes leading to up-regulation of TGF-ß 
signaling components suggests a post-translational mechanism of antibody-mediated 
complement signaling, we sought to identify the specific proteasome population that 
was targeted in antibody-mediated complement signaling as it is both unlikely that 
antibody-mediated complement signaling shuts down the proteasome function entirely 
in a cell and the proteomics screen we initially performed found differential protein up-
regulation in the MG132-treated constitutively active Rab5 group and the PRA-treated 
constitutively active Rab5 group, as well as  compared to the PRA-treated wild-type 
Rab5 group. In order to interrogate the specific lid components that are targeted by 
antibody-mediated complement signaling, we pulled down a common core proteolytic 
component and western blotted for specific proteasome components that were 
representative of different proteasome populations, ultimately finding the PA200 
proteasome population as being selectively inactivated by PRA treatment. This finding 
suggested that antibody-mediated complement fixation leads to selective degradation or 
targeting of the PA200 proteasome population, making it a proteasome population of 
interest.  
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However, to show that the PA200 proteasome population selectively targets 
antibody-mediated complement signaling proteins including ZFYVE21 and TGF-ß 
superfamily proteins, we needed to show that the PA200 proteasome indeed targets 
these pathway mediators. To show this, we transfected HUVEC with siRNA against a 
PA200 proteasome lid component to knock-down PA200 proteasome function in order 
to establish its role. One limitation of this strategy, seen in our western blot 
confirmation of knock-down, was the limited efficiency of knock-down as compared to 
other methods such as knock-out models. Namely, the PSMC2 lanes that were blotted 
showed partial knock-down, but not complete. However, differences in levels of 
ZFYVE21 mediators and TGF-ß mediators were still appreciated in the control siRNA 
groups compared to the PSMC2 siRNA groups in both homeostatic as well as PRA-
treated groups. In the future, different strategies can be employed in order to have 
better knock-down efficiency with the PSMC2 siRNA in order to more clearly delineate 
these differences. Thus, our siRNA studies established that the PA200 proteasome 
population is implicated in targeting these antibody-induced complement signaling 
mediators including ZFYVE21 pathway proteins as well as TGF-ß proteins. Combined 
with the earlier co-IP studies of the proteasome core protein western blots, a pathway 
can be deduced whereby antibody-mediated complement fixation leads to selective 
inactivation of the PA200 proteasome population, further leading to inhibited 
degradation of ZFYVE21 signaling proteins and TGF-ß proteins. 
An interesting phenomenon noted through the siRNA knock-down studies 
performed was the fact that PRA treatment, or antibody-mediated complement fixation, 
did not lead to breakdown of the PSMC2 lid component, instead, led to disruption of its 
proteasome function as evidenced by post-translational rescue of ZFYVE21 and TGF-ß 
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pathway mediators. This finding implies that the lid components themselves are not 
targeted for destruction, but rather are either unable to associate with the core 
proteolytic proteasome elements or are in some way disrupted from their binding 
capacity. Again, when looking at the core PSMA2 co-IP experiments, it would appear 
that the core proteolytic element is dissociated from the PA200 lid components 
following antibody-mediated complement fixation, leaving proteasome lid components 
bound to ZFYVE21 and TGF-ß mediators. 
In order to determine the spatial relationship that these proteasome components 
have to the Rab5 endosomes that ultimately serve as the platform for previously 
described antibody-mediated complement signaling via ZFYVE21, we turned back to our 
initial proteasomal analysis that were performed on the Rab5 endosomes, specifically 
comparing the untreated Rab5 constitutively active group, the pan-proteasome MG132-
treated Rab5 constitutively active group, and the PRA-treated Rab5 wild-type group and 
noted numerous proteasome components were differentially recruited to Rab5 
endosomes in the PRA-treated group. Furthermore, when pulling down for a 
proteasomal lid component PSMC2 and blotting for Rab5 and other antibody-mediated 
complement signaling mediators after PRA treatment, we found increased associations 
of the proteasomal lid component PSMC2 with all of the above, suggesting that PRA 
treatment leads to recruitment of this PA200 lid component to Rab5 endosomes, likely 
while carrying ZFYVE21 and TGF-ß pathway proteins originally destined for 
degradation. It was also noted that at time 0 during the co-IP, the PSMC2 lid 
component was already found to be bound to some amount of ZFYVE21 and TGF-ß 
pathway proteins, likely indicating active degradation. 
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Taken all together, these experiments serve to suggest that proteasomes do not 
simply function to basally degrade antibody-mediated complement signaling proteins 
such as ZFYVE21 and TGF-ß proteins while under homeostatic conditions, but also 
potentially serve a second role as a chaperone in bringing these pathway mediators to 
the correct platform of Rab5 endosomes in order to perform their effector function. In 
other words, at baseline, the PA200 lid components bind to ZFYVE21 and TGF-ß 
signaling proteins and are associated with proteasomal core components that lead to 
degradation. However, upon introduction of antibody-mediated complement fixation, 
the PA200 lid components are dissociated from their core proteolytic element and are 
instead translocated to Rab5 endosomes, bringing their cargo (ZFYE21 and TGF-ß 
signaling proteins) along with them to ensure proper co-localization for further 
downstream signaling changes. 
 
To summarize briefly and recap at this stage, we have shown that for antibody-
mediated complement fixation, the TGF-ß superfamily of proteins follows in our 
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proposed two-step model. Namely, we have shown that inhibition of proteasomes leads 
to rapid upregulation of TGF-ß components and have more specifically shown a role for 
the PA200 proteasome population as mediating this effect. Furthermore, we have 
shown that after rescue from basal degradation by proteasomes, these proteins are 
recruited via PA200 proteasome lid components to Rab5 endosomes which serve as a 
platform for further downstream signaling. This would suggest that the same 
proteasome components that specifically target these pathway mediators for 
degradation under homeostatic conditions may dually serve a novel chaperone function 
in aiding recruitment to the proper signaling platform. In this updated model, 
proteasomes may serve as a stress sensor and chaperone. In basal homeostatic states, 
they degrade pro-inflammatory proteins. However, with introduction of a stressor such 
as antibody-mediated fixation of complement, proteasomes bound to pro-inflammatory 
proteins are recruited to Rab5 endosomes and disassembled, bringing their pro-
inflammatory mediators along in the process in order for them to co-localize and 
perform downstream signaling function. Through this, cells are able to rapidly adapt 
and respond to stressors without undergoing the typical process of transcription and 
translation. 
Through identification of the proteasome as being potentially central in the 
pathogenesis of antibody-mediated complement signaling and one arm of allograft 
vasculopathy, one may turn towards the clinical correlate in potential drugs targeting 
proteasomes. Interestingly, as there is a well-described B-cell component to allograft 
vasculopathy, efforts are already underway in studying the effect modulation of this 
response has. Specifically, as described above in the literature review, the renal 
transplant community has initiated the BORTEJECT Study, a Phase II study using 
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bortezumib, a proteasome inhibitor, in preventing late allograft loss. Given the novel 
findings that proteasomes may play in this pathway as described here, there may be a 
dual function of preventing antibody-mediated complement signaling as well. 
While we have been working up the more global mechanism by which we believe 
antibody-mediated complement fixation leads to rapid signaling changes in endothelial 
cells, we have also performed preliminary experiments in order to better characterize 
the TGF-ß response that is induced through this pathway. Specifically, we have found 
that antibody-induced complement activation generates TGF-ß1 and TGF-ß2 in 
endothelial cells via ELISA in preliminary studies. We have also seen preliminary data 
that TGF-ß signaling elicits endothelial cell activation via both RT-qPCR as well as T-
Cell adhesion studies. Last, to better understand dynamics of co-localization, IHC would 
be most informative in being able to observe the interactions between proteasome 
components, ZFYVE21 and TGF-ß pathway mediators, and Rab5 endosomes pre- and 
post-PRA treatment and those experiments are tentatively planned. 
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7. COVID-19 Statement: 
Much of the research presented was performed in the first year I was engaged in 
the lab and my original plans were to resume research in the summer/winter 2020. As 
much of the research involves physically being at the lab, these were disrupted as labs 
were closed for much of the early summer. Moreover, my board exams, sub-internship, 
and electives were all cancelled or pushed back during this time. In order to make the 
most of my time then when my in-person activities were limited, I chose to engage in 
research through reading in order to frame the work that is presented here as well as 
focus more on thesis writing. When clinical electives and sub-internships were opened 
again, I opted to complete those before returning to reading and thesis writing in order 
to ensure I would be able to apply to residency this cycle. 
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